ArticleMedicine2025
18F-AV45 PET-CT screening for systemic amyloidosis: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSystemic AL amyloidosis is a complex, multi-system disease with diverse clinical manifestations. Early and definite diagnosis helps to improve the prognosis. PATIENT CONCERNS: At the beginning stage of the disease, the patient only presented with liver enlargement and abnormal liver function. DIAGNOSES: Conventional echocardiography "ECG" amyloidosis screening spot tracking imaging, etc. Pathology is the gold standard for diagnosis.
interventionsElimination of clonal plasma cells or B cells that produce abnormal light chains. For eligible patients, autologous stem cell transplantation is the first choice. OUTCOMES: Systemic AL amyloidosis is often misdiagnosed due to a lack of typical symptoms and imaging signs. LESSONS: This case highlights the patients with atypical clinical manifestations of AL amyloidosis, and the diagnosis should be made early to improve the prognosis. If there are risks and difficulties in pathological diagnosis, the cumulative organs can be indirectly evaluated with 18F-florbetapir positron emission tomography-computed tomography. Subsequent indirect diagnosis through less invasive, more accessible abdominal or rectal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.